Liminatus Pharma, Inc.
LIMN
$0.18
$0.00-2.17%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 319.36% | 278.67% | 92.47% | -33.00% | -39.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.80% | -49.38% | -59.56% | -64.60% | -30.90% |
| Operating Income | 18.80% | 49.38% | 59.56% | 64.60% | 30.90% |
| Income Before Tax | -178.57% | 52.53% | 84.65% | 62.08% | 28.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -178.57% | 52.53% | 84.65% | 62.08% | 28.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -178.57% | 52.53% | 84.65% | 62.08% | 28.84% |
| EBIT | 18.80% | 49.38% | 59.56% | 64.60% | 30.90% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -79.66% | 61.46% | 75.32% | 19.18% | -274.49% |
| Normalized Basic EPS | 11.14% | 20.54% | 40.82% | 19.09% | -274.56% |
| EPS Diluted | -79.66% | 61.46% | 75.32% | 19.18% | -274.49% |
| Normalized Diluted EPS | 11.14% | 20.54% | 40.82% | 19.09% | -274.56% |
| Average Basic Shares Outstanding | 47.75% | -43.08% | -67.54% | -77.85% | -82.92% |
| Average Diluted Shares Outstanding | 47.75% | -43.08% | -67.54% | -77.85% | -82.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |